Suprit Gupta
Overview
Explore the profile of Suprit Gupta including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
752
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Jain A, Heremans I, Rademaker G, Detomasi T, Hernandez G, Zhang J, et al.
bioRxiv
. 2024 Dec;
PMID: 39713462
One Sentence Summary: LyLAP degrades transmembrane proteins to sustain high endocytosis and lysosomal membrane stability in pancreatic cancer.
2.
Gautam S, Dalal V, Sajja B, Gupta S, Gulati M, Dwivedi N, et al.
Cancer Lett
. 2022 Jun;
544:215801.
PMID: 35732216
Delivery of therapeutic agents in pancreatic cancer (PC) is impaired due to its hypovascular and desmoplastic tumor microenvironment. The Endothelin (ET)-axis is the major regulator of vasomotor tone under physiological...
3.
Kilinc S, Paisner R, Camarda R, Gupta S, Momcilovic O, Kohnz R, et al.
Dev Cell
. 2021 Jun;
56(13):1989-2006.e6.
PMID: 34118203
Oncogenes can alter metabolism by changing the balance between anabolic and catabolic processes. However, how oncogenes regulate tumor cell biomass remains poorly understood. Using isogenic MCF10A cells transformed with nine...
4.
Gupta S, Yano J, Mercier V, Htwe H, Shin H, Rademaker G, et al.
Nat Cell Biol
. 2021 Mar;
23(3):232-242.
PMID: 33686253
Lysosomes must maintain the integrity of their limiting membrane to ensure efficient fusion with incoming organelles and degradation of substrates within their lumen. Pancreatic cancer cells upregulate lysosomal biogenesis to...
5.
Yamamoto K, Venida A, Yano J, Biancur D, Kakiuchi M, Gupta S, et al.
Nature
. 2020 May;
581(7806):100-105.
PMID: 32376951
Immune evasion is a major obstacle for cancer treatment. Common mechanisms of evasion include impaired antigen presentation caused by mutations or loss of heterozygosity of the major histocompatibility complex class...
6.
Gupta S, Prajapati A, Gulati M, Gautam S, Kumar S, Dalal V, et al.
Neoplasia
. 2020 Jan;
22(2):98-110.
PMID: 31923844
Endothelin-1 (ET-1) and its two receptors, endothelin receptor A (ETR) and endothelin receptor B (ETR) exhibit deregulated overexprerssion in pancreatic ductal adenocarcinoma (PDAC) and pancreatitis. We examined the expression pattern...
7.
Macha M, Rachagani S, Qazi A, Jahan R, Gupta S, Patel A, et al.
Oncotarget
. 2017 Apr;
8(13):20961-20973.
PMID: 28423495
The dismal prognosis of locally advanced and metastatic squamous cell carcinoma of the head and neck (HNSCC) is primarily due to the development of resistance to chemoradiation therapy (CRT). Deregulation...
8.
Muniyan S, Haridas D, Chugh S, Rachagani S, Lakshmanan I, Gupta S, et al.
Genes Cancer
. 2016 Jul;
7(3-4):110-124.
PMID: 27382435
MUC16, a heavily glycosylated type-I transmembrane mucin is overexpressed in several cancers including pancreatic ductal adenocarcinoma (PDAC). Previously, we have shown that MUC16 is significantly overexpressed in human PDAC tissues....
9.
Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells
Lakshmanan I, Seshacharyulu P, Haridas D, Rachagani S, Gupta S, Joshi S, et al.
Oncotarget
. 2015 Jun;
6(25):21085-99.
PMID: 26035354
Several studies have demonstrated that MUC4 is involved in progression and metastasis of pancreatic cancer (PC). Here, we report that HER3/MUC4 interaction in HER2 low cells is critical in driving...
10.
Gupta S, Batra S, Jain M
Methods Mol Biol
. 2014 Feb;
1141:147-57.
PMID: 24567137
Antibodies have been conjugated to radionuclides for various in vitro and in vivo applications. Radiolabeled antibodies have been used in clinics and research for diagnostic applications both in vitro as...